Complement Therapeutics to Present Preclinical Proof of Concept Data on CTx001 at the 2023 Association for Research in Vision and Ophthalmology Congress
Munich, Germany – 20th April 2023 – Complement Therapeutics GmbH (CTx), a preclinical stage biotechnology company developing novel therapeutics for complement-mediated diseases, today announced that pre-clinical data for its lead asset, CTx001, a gene therapy focused on treating geographic atrophy, a form of dry age-related macular degeneration, will be featured in posters at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2023 to be held on 23-27th April 2023 in New Orleans, USA.
ARVO Poster Details:
Title: CTx001, a gene therapy for the treatment of geographic atrophy in aged-related macular degeneration
Session: 414, Gene and Cell Therapy, April 26, 2023, from 10:30 AM to 12:30 PM
Presentation Number: #3852
Poster Board Number: #B0132
About Complement Therapeutics GmbH:
Complement Therapeutics GmbH (CTx) is a German headquartered early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.
Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for GA, a leading cause of blindness. Additional programs will evaluate potential therapeutic opportunities in other complement-mediated conditions.
The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable the quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.
The Company has subsidiaries in the UK (Complement Therapeutics Ltd) and in the USA (Complement Therapeutics Inc) as well as research laboratories in Stevenage, UK.
For more information please visit: https://complementtx.com/
Dr Rafiq Hasan, CEO and Managing Director
Complement Therapeutics GmbH